雷珠单抗和康柏西普对分支静脉阻塞合并黄斑水肿BCVA、PLT及CMT的影响

Effects of ranibizumab and compaqip on BCVA,PLT and CMT in branch vein occlusion combined with macular edema

探讨雷珠单抗和康柏西普对分支静脉阻塞合并黄斑水肿BCVA、PLT及CMT的影响。选择2017年6月至2018年5月在我院接受治疗的视网膜分支静脉阻塞合并黄斑水肿患者48例(48眼)进行研究。采用随机数字表法将患者分为2组,每组各24例(24眼)。两组患者均由同一组具丰富临床经验的医护人员进行治疗,对照组在常规治疗基础上加以雷珠单抗,观察组采用康柏西普。对比两组患者疗效、BCVA、PLT、CMT及舒适度。对照组总有效率为75.00%,与观察组的87.50%差异无统计学意义(P>0.05)。治疗后两组患者CMT均明显下降,BCVA、PLT均明显上升(均P<0.05),但两组患者治疗前后对比差异均无统计学意义(P>0.05)。两组患者舒适度对比差异无统计学意义(P>0.05)。两组患者治疗期间血常规、尿常规、便常规、肝肾功能与心电图检查结果均未出现异常,对照组出现3例(12.50%)不良反应;观察组出现2例(8.33%)不良反应,两组患者不良反应发生率差异无统计学意义(P>0.05)。康柏西普在治疗分支静脉阻塞合并黄斑水肿时疗效与雷珠单抗相当,两者均可明显改善BCVA、PLT及CMT,两组不良反应发生率无明显差异。

To investigate the effects of Razumab and Compoxip on BCVA,PLT and CMT in patients with branch vein occlusion complicated with macular edema.A total of(48 eyes)48 patients with retinal branch vein occlusion and macular edema who were treated in our hospital from June 2017 to May 2018 were enrolled.Patients were divided into 2 groups by random number table method,twenty four cases in each group(24 eyes).Both groups of patients were treated by the same group of medical staff with rich clinical experience.The control group received ranibizumab on the basis of conventional treatment,and the observation group used Compaqip.The efficacy,BCVA,PLT,CMT and comfort of the two groups were compared.The total effective rate of the control group was 75.00%,which was not significantly different from the 87.50%of the observation group(P>0.05).After treatment,the CMT of both groups decreased significantly,and BCVA and PLT increased significantly(P<0.05).However,there was no significant difference between the two groups(P>0.05).There was no significant difference in comfort between the two groups(P>0.05).There were no abnormalities in blood routine,urine routine,stool routine,liver and kidney function and electrocardiogram during the treatment of the two groups.There were 3 cases(12.50%)of adverse reactions in the control group and 2 cases(8.33%)in the observation group.There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Composcipation in the treatment of branch vein occlusion with macular edema is comparable to that of ranibizumab,both of which can significantly improve BCVA,PLT and CMT.There was no significant difference in the incidence of adverse reactions between the two groups.